Connect with a Medical Science Liaison in your region

  • Enter your Zip Code
  • Select a calendar date
  • Select a time, confirm, and enter details

Tell us what interests you

How interested are you in learning more about the following topics?

The hypothetical role of targeted gene therapy in modulating BK channel expression
The role of beta-3 adrenergic receptor agonists in the treatment of patients with OAB
A comprehensive treatment overview for OAB
Treatment approaches in OAB
Recent publications on vibegron and OAB

Success!

We’ve received your completed survey. Thanks for participating.

Close

Thank You.

We’ve received your inquiry. Thank you for contacting Urovant Sciences Medical Affairs. We will contact you shortly.

Close

Take Survey

Welcome to
Urovant Sciences Medical Affairs

This site is intended as an educational resource for U.S. healthcare providers. The content may include information about products or potential uses that have not been approved by the U.S. Food and Drug Administration.

This information is not intended to be promotional or deliver medical advice.

Choose an option:

I’m a U.S. healthcare professional I’m a U.S. patient or caregiver

You are exiting this website. Are you sure you want to leave?

By clicking the YES link, you will be leaving the Urovant Sciences Medical Affairs website and redirected to the Sumitomo Pharma America, Inc. (SMPA) website.

NO, take me back YES, exit this website

This information is intended for US healthcare professionals For Patients

Urovant sciences

Adverse Events

833-UROVANT (Option 1)

24 hours/day, 7 days/week

Product Complaints

833-UROVANT (Option 1)

Monday – Friday, 8am – 5pm PT

UROVANT, UROVANT SCIENCES, and the UROVANT SCIENCES logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries. All other trademarks are the property of their respective owners. © 2023 Urovant Sciences. All rights reserved. AB-VB-US-21-00006 (v3.0)